This segment focuses on the research, development, and clinical trials of novel therapeutics for the treatment of Refractory Chronic Cough (RCC), a condition characterized by persistent cough that is unresponsive to standard treatments. The primary focus is on BLU-5937, a P2X3 receptor antagonist. Research and development activities include Phase II clinical trials to evaluate the efficacy and safety of BLU-5937 in RCC patients. The technology used involves small molecule drug development and targeted therapies. The patient impact is significant, as RCC severely impacts quality of life. Market positioning is within the pharmaceuticals sector, with a competitive advantage in targeting a specific unmet medical need. Future opportunities include expanding the application of BLU-5937 to other cough hypersensitivity indications. Regulatory and clinical aspects involve FDA approval processes and adherence to clinical trial protocols. Partnerships and collaborations are essential for clinical trial execution and commercialization.